SetPoint Medical is pioneering bioelectronic medicine therapies to treat autoimmune diseases such as rheumatoid arthritis, Crohn's Disease, and multiple sclerosis. The company has developed a proprietary bioelectronic medicine platform consisting of a micro-regulator programmed via a unique prescription pad-based interface, offering a safe and efficacious alternative to drugs.

Shaw Warren

Kevin Tracey

Jim Broderick

SetPoint Medical

SetPoint Medical is developing novel bioelectronic medicine therapies to treat those who suffer from autoimmune diseases such as rheumatoid arthritis, Crohn's Disease and multiple sclerosis.  The company has developed a proprietary and innovative bioelectronic medicine platform consisting of a micro-regulator programmed via a unique prescription pad based interface.  This novel therapy has the potential to provide patients and healthcare providers with a safe and efficacious alternative to drugs, while costing payers significantly less than  biologic therapies.

Runway Growth Capital

Action Potential Venture Capital

Euclidean Capital

Boston Scientific

Citta Capital

New Enterprise Associates

Gilmartin Capital LLC

SVE Capital

Richard King Mellon Foundation

Shangbay Capital

CITA Investissement

Midas Capital

Morgenthaler Ventures

Topspin Fund

Revelation Partners

This holiday season, we want to take a moment to extend our gratitude to all the SetPoint employees who worked so hard to make this year special. Your passion and dedication to developing this novel therapy to help RA patients is deeply inspiring! We celebrated this year’s numerous achievements with some great food and holiday cheer.

Wishing each of you and your loved ones a holiday season brimming with joy, peace, and good health.

This #Thanksgiving, we want to extend our profound gratitude to all the incredible people who make the RESET-RA study possible. We deeply appreciate the dedication and hard work of our partners, investigators, and staff. And to our RA study participants, your resilience and strength are truly inspiring. You are appreciated immensely! We look forward to our continued collaboration with you as we evaluate the therapeutic potential of this technology. Wishing our entire community a warm and joyful Thanksgiving!

🧟‍♀️ 🧛‍♂️ #HappyHalloween2023 🧛‍♀️ 🧟‍♂️ 

Each year, we are amazed at the ingenuity and creativity of our team!

#TheSetPointAdvantage

Metric
Company Name	SetPoint Medical
Symbol
MSH ID	COM:SETPOINTMEDICAL
Market	PRIVATE
Sector	Healthcare
Industry	Medical Equipment Manufacturing
Country	US
Stage
Employee Count	81
Website	setpointmedical.com
LinkedIn	setpoint-medical
Founders

Metric
Market Cap	111.57M
Enterprise Value
Monthly Web Traffic	250
Web Traffic Growth	1.40
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:SETPOINTMEDICAL

SetPoint Medical

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue